FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to immunology and biotechnology. Claimed are versions of antibodies or their functional fragments, which are bound with receptor of human insulin-like growth factor I IGF-IR, and/or natural binding of its ligands IGF1 and/or IGF2 and/or are capable of specific inhibition of tyrosine kinase activity of said IGF-IR. Antibodies contain respective CDR sections of light and heavy chains. Described is mouse hybridoma I-3193 for production of antibodies. Composition for prevention or treatment of cancer, based on antibody application. Described is application of antibodies and/or composition for obtaining respective medication. Claimed is method of diagnostics in vitro of diseases, caused by over-expression or insufficient expression of receptor IGF-I based on antibodies..
EFFECT: invention application ensures antibodies able to bind with isophorms A and B insulin, insulin/ IGF-1 of hybrid receptors which can be applied in medicine for tumour treatment.
15 cl, 8 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTIBODIES TO IGF-IR AND THEIR APPLICATION | 2006 |
|
RU2434882C2 |
| BINDING PROTEINS SPECIFIC TO INSULIN-LIKE GROWTH FACTORS, AND USING THEM | 2013 |
|
RU2549703C2 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706959C2 |
| RECEPTOR ANTAGONISTS FOR TREATING METASTATIC CANCER | 2009 |
|
RU2455026C2 |
| PDGFRα ANTIBODIES FOR TREATING SECONDARY BONE TUMOUR | 2006 |
|
RU2502523C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706967C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| METHOD FOR TREATING RESISTANT HUMAN TUMORS WITH EPIDERMIS GROWTH FACTOR RECEPTORS ANTAGONISTS | 2000 |
|
RU2294761C2 |
| ANTIBODY AGAINST IGF-I RECEPTOR | 2018 |
|
RU2785305C2 |
